Dylan Dupuis
Stock Analyst at Roth MKM
(2.78)
# 1,982
Out of 4,996 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $28 | $2.64 | +960.61% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $6.05 | +81.82% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $7.64 | +201.05% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $25.57 | +25.15% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $2.64
Upside: +960.61%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $6.05
Upside: +81.82%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $7.64
Upside: +201.05%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $25.57
Upside: +25.15%